Stock Market News

Aclaris Therapeutics initiates Phase 1 trial for ATI-052 antibody

Jun 25, 2025 - 12:42
 0
Aclaris Therapeutics initiates Phase 1 trial for ATI-052 antibody
Read More

Tags:

Previous Article

H.C. Wainwright reiterates buy rating on US Gold stock at $15 target

Next Article

H.C. Wainwright reiterates buy rating on Anixa Biosciences stock

Related Posts

Exclusive-Walmart’s Flipkart secures approval for direct lending in India

Exclusive-Walmart’s Flipkart secures approval for direc...

Jun 5, 2025  0

Pagaya stock price target maintained at $26 by JMP on margin outlook

Pagaya stock price target maintained at $26 by JMP on m...

Jun 24, 2025  0

Beyond the headlines: explaining Trump's Gulf 'trillions'

Beyond the headlines: explaining Trump's Gulf 'trillions'

May 16, 2025  0